Rectal cancer with liver metastases
Conditions
Interventions
Group 1:100-300µm pre-loading irinotecan caliis sub-aperture drug carrying microspheres
Group 2:Preloading of 300-500µm irinotecan caliis sub-aperture drug carrying microspheres
Sponsors
Yantai Yuhuangding Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years; 2. The patients were diagnosed by pathology and imaging and met the criteria of unresectable colorectal cancer in China Guidelines for Diagnosis and Treatment of Colorectal Cancer (2020 Edition); 3. Dysfunction of centerlessness, brain, kidney and other important organs; 4. A or B Child-Pugh; 5. ECOG score 0-2; 6. The patient is expected to survive for more than 3 months. The subjects voluntarily joined the study and signed the informed consent; 7. With good compliance and cooperated with the follow-up.
Exclusion criteria
Exclusion criteria: 1. Child-Pugh C and above, including jaundice, hepatic encephalopathy, refractory ascites or hepatorenal syndrome; 2. Severe coagulation dysfunction; 3. Total obstruction of the main portal vein, and less collateral vessels; 4. Cachexia or multiple organ failure; 5. Renal dysfunction (urinary creatinine > 20 mg/L or creatinine clearance < 30 mL/min); 6. Contraindications to interventional therapy; 7. Patients with poor compliance such as floating population; 8. patients who have participated in other clinical trials of investigational drugs or devices within four weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective remission rate, ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival, PFS;Overall survival, OS; | — |
Countries
China
Contacts
Public ContactWang Tao
Yantai Yuhuangding Hospital
Outcome results
None listed